Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of ...
Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...
9don MSN
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
(Reuters) -Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its ...
Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...
The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
Investor's Business Daily on MSN2h
Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected HitchHims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback